Related Experiment Video
Updated: Dec 13, 2025

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
KRAB domain of ZFP568 disrupts TRIM28-mediated abnormal interactions in cancer cells
Janani Kumar1, Gundeep Kaur1, Ren Ren1
1Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Interactions of KRAB (Krüppel-associated box)-associated protein KAP1 [also known as TRIM28 (tripartite motif containing protein 28)] with DNA-binding KRAB zinc finger (KRAB-ZF) proteins silence many transposable elements during embryogenesis. However, in some cancers, TRIM28 is upregulated and interacts with different partners, many of which are transcription regulators such as EZH2 in MCF7 cells, to form abnormal repressive or activating complexes that lead to misregulation of genes. We ask whether a KRAB domain-the TRIM28 interaction domain present in native binding partners of TRIM28 that mediate repression of transposable elements-could be used as a tool molecule to disrupt aberrant TRIM28 complexes. Expression of KRAB domain containing fragments from a KRAB-ZF protein (ZFP568) in MCF7 cells, without the DNA-binding zinc fingers, inhibited TRIM28-EZH2 interactions and caused degradation of both TRIM28 and EZH2 proteins as well as other components of the EZH2-associated polycomb repressor 2 complex. In consequence, the product of EZH2 enzymatic activity, trimethylation of histone H3 lysine 27 level, was significantly reduced. The expression of a synthetic KRAB domain significantly inhibits the growth of breast cancer cells (MCF7) but has no effect on normal (immortalized) human mammary epithelial cells (MCF10a). Further, we found that TRIM28 is a positive regulator of TRIM24 protein levels, as observed previously in prostate cancer cells, and expression of the KRAB domain also lowered TRIM24 protein. Importantly, reduction of TRIM24 levels, by treatment with either the KRAB domain or a small-molecule degrader targeted to TRIM24, is accompanied by an elevated level of tumor suppressor p53. Taken together, this study reveals a novel mechanism for a TRIM28-associated protein stability network and establishes TRIM28 as a potential therapeutic target in cancers where TRIM28 is elevated. Finally, we discuss a potential mechanism of KRAB-ZF gene expression controlled by a regulatory feedback loop of TRIM28-KRAB.
Insights
A synthetic KRAB domain disrupts cancer-driving TRIM28 complexes, inhibiting breast cancer cell growth and lowering TRIM28 and EZH2. This reveals TRIM28 as a potential therapeutic target in cancers.
Area of Science:
- Epigenetics and Gene Regulation
- Cancer Biology
- Molecular Therapeutics
Background:
- TRIM28 (tripartite motif containing protein 28) normally silences transposable elements via interactions with KRAB zinc finger (KRAB-ZF) proteins.
- In some cancers, elevated TRIM28 forms aberrant complexes with proteins like EZH2, leading to gene misregulation and cancer cell proliferation.
- The KRAB domain is the key interaction motif mediating TRIM28's role in gene silencing.
Purpose of the Study:
- To investigate if a KRAB domain can be used as a tool to disrupt aberrant TRIM28 complexes in cancer.
- To evaluate the therapeutic potential of targeting TRIM28-EZH2 interactions in breast cancer cells.
Main Methods:
- Expression of KRAB domain-containing fragments (from ZFP568) in MCF7 breast cancer cells.
- Analysis of TRIM28, EZH2, and TRIM24 protein levels and interactions.
- Assessment of histone H3 lysine 27 trimethylation and cell growth inhibition.
- Comparison of effects on cancer cells (MCF7) versus normal mammary epithelial cells (MCF10a).
Main Results:
- KRAB domain expression inhibited TRIM28-EZH2 interactions and led to degradation of TRIM28, EZH2, and other PRC2 components.
- This resulted in reduced H3K27 trimethylation and significantly inhibited MCF7 breast cancer cell growth, with no effect on normal cells.
- KRAB domain expression also reduced TRIM24 levels, leading to increased tumor suppressor p53, and TRIM28 was identified as a positive regulator of TRIM24.
Conclusions:
- A synthetic KRAB domain can effectively disrupt aberrant TRIM28 complexes, offering a novel therapeutic strategy for cancers with elevated TRIM28.
- The study uncovers a new protein stability network involving TRIM28 and TRIM24, highlighting TRIM28 as a viable therapeutic target.
- TRIM28-mediated regulation of KRAB-ZF protein expression via a feedback loop is proposed.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Restarting Stalled Replication Forks
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Epigenetic Regulation

